Drugging this type of GPCR with small molecules has its challenges say Jeff Finer, chief executive of Septerna, a biotech based in south San Francisco, US
So whether India becomes the worlds pharmacy for cheap weight-loss drugs will depend on the choices it makes now
Retatrutide could be a new and strong choice for people who deal with obesity and problems with how their body uses food
In 2026, the number of people with no commercial insurance coverage for Wegovy increased by 42 percent compared to 2025
Klebanoff: Prior authorization requires clinicians to justify a patients need for treatment and get insurer approval for coverage
Tirzepatide, on the other hand, is a dual agonist, targeting both the GLP-1 and GIP receptors, offering enhanced glucose control and weight loss by combining the effects of both incretin hormones